CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 176 enrolled
Drug / intervention
Imatinib mesylate +1 moredrug
Likely dose
Imatinib mesylate 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01097694
NCT01097694Phase 2Completed
CompareCT.gov

A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Brigham and Women's Hospital·interventional·Posted Apr 2, 2010·Updated May 19, 2017

In Brief

A Phase 2 clinical trial evaluating Imatinib mesylate and Placebo for Asthma. Completed, enrolled 176 participants across 7 sites.

Detailed Summary

The purpose of this study is to see whether a new investigational drug (Imatinib) may help improve asthma in people whose symptoms are not well controlled with high dose inhaled corticosteroid treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
CollaboratorsBaim Institute for Clinical Research, National Heart, Lung, and Blood Institute (NHLBI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2, 2010
Enrollment StartNov 1, 2010
Primary CompletionAug 1, 2015
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 16.3 years ago

Interventions

Imatinib mesylatedrug

Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.

Placebodrug

Placebo